AAM
CRSP icon

Azzad Asset Management’s CRISPR Therapeutics CRSP Stock Holding History

Azzad Asset Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-3,553
Closed -$223K – 396
2022
Q1 		$223K Buy
3,553
+545
+18% +$34.2K 0.03% 314
2021
Q4 		$228K Buy
3,008
+151
+5% +$13.2K 0.03% 317
2021
Q3 		$320K Sell
2,857
-63
-2% -$7.91K 0.05% 305
2021
Q2 		$473K Buy
2,920
+48
+2% +$5.84K 0.07% 287
2021
Q1 		$350K Buy
+2,872
New +$434K 0.06% 287

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Azzad Asset Management's CRSP Position: Q2 2022 in Review

Azzad Asset Management sold out of CRISPR Therapeutics (CRSP) in Q2 2022, closing a stake of 3,553 shares — an estimated $223K sold.

Azzad Asset Management first reported a position in CRSP in Q1 2021 and held it in 5 quarters. The position peaked at $473K in Q2 2021. 435 funds tracked by Wall St. Rank hold CRSP as of Q2 2022.

  • Azzad Asset Management reported no remaining CRISPR Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Azzad Asset Management sold 3,553 CRISPR Therapeutics shares in Q2 2022, an estimated $223K.
  • Azzad Asset Management first reported a position in CRISPR Therapeutics in Q1 2021 and held it in 5 quarters.
  • Azzad Asset Management's CRISPR Therapeutics position peaked at $473K in Q2 2021.
  • 435 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2022.

Based on Azzad Asset Management's 13F filing for Q2 2022, filed 1 Apr 2024.